For hidradenocarcinoma, apocrine carcinoma, and signet-ring call/histiocytoid carcinoma, HER2 inhibitors or selective estrogen receptor modulators may be administered [53,54,55,56,57,58]. The gene discussed is ERBB2; the disease is apocrine adenocarcinoma.